Posted by Michael Wonder on 29 Oct 2018
Mavenclad (cladribine tablets) receives positive CADTH Canadian Drug Expert Committee recommendation
29 October 2018 - Funding recommendation marks an important step to provide access to this innovative new oral treatment for Canadians living with relapsing-remitting multiple sclerosis.
Merck KGaA is pleased to announce that the CADTH Canadian Drug Expert Committee has issued a positive recommendation that Mavenclad (cladribine tablets) be reimbursed by public drug plans as a treatment for adult patients living with relapsing-remitting multiple sclerosis (RRMS).
The next step in the reimbursement process is to work with the pan-Canadian Pharmaceutical Alliance to negotiate for the funding of Mavanclad by provincial and territorial drug plans. Mavenclad is also currently available through the majority of plans from private insurers.
